MedTrace Logo

M. Avium WGS During Mav-PD Treatment

NCT06266442 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-05-21

No results posted yet for this study

Summary

This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere.

The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.

Conditions

  • Mycobacterium Avium
  • Mycobacterium Infections, Nontuberculous
  • Mycobacterium Infections
  • Nontuberculous Mycobacterial Lung Disease
  • Respiratory Tract Diseases

Interventions

OTHER

Whole genome sequencing testing

Whole genome sequencing

Sponsors & Collaborators

  • Western University, Canada

    collaborator OTHER

  • Public Health Ontario Laboratory, Canada

    collaborator UNKNOWN

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Theodore Marras, MD · UHN

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-13
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06266442 on ClinicalTrials.gov